Macquarie Starts Allergan (AGN) at Outperform
AGN Hot Sheet
Rating Summary:9 Buy, 5 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Macquarie initiates coverage on Allergan (NYSE: AGN) with an Outperform rating and $75 price target.
Allergan closed at $62.56 yesterday with a 52-week range of $50.22-$66.95. Shares have not traded yet today.
Allergan, Inc., a multi-specialty healthcare company, discovers, develops, and commercializes specialty pharmaceutical, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention, urological, and other specialty markets worldwide.
Allergan closed at $62.56 yesterday with a 52-week range of $50.22-$66.95. Shares have not traded yet today.
Allergan, Inc., a multi-specialty healthcare company, discovers, develops, and commercializes specialty pharmaceutical, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention, urological, and other specialty markets worldwide.
You May Also Be Interested In
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
- Needham & Company Reiterates a 'Buy' on UQM Technologies (UQM); Increasing EV Adoption
- NFP Announces Marshall A. Heinberg Joins Board of Directors
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
